Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced that the ReCET Clinical Study has reached full enrollment. A ...
Endogenex announced today that it completed enrollment in the ReCET clinical study of its endoscopic diabetes treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results